7 results
Primary objective: prospective evaluation of the relationship between lean body weight and anti-Xa activity of 5700 IU nadroparin 4 hours after subcutaneous administration in morbidly obese patients.Secundary objectives: - Correlation between other…
The aim of this study is to determine the accumulation of nadroparin used in renal insufficient patients with VTE, by measuring anti-Xa levels.
The primary objective is to demonstrate the non-inferiority of edoxaban to standard of care (SOC; including low molecular weight heparin (LMWH), or vitamin K antagonist (VKA)) in the treatment and secondary prevention of VTE in pediatric subjects…
To establish whether niraparib single agent treatment in advanced BRCA1-like, HER2 negative breast cancer patients deserves to be further studied
The purpose of this study is to determine the need for thromboprofylaxis in patients being treated in a below-knee plaster cast after trauma of a lower extremity and if there is, to assess if both of the two tested prophylactic treatments are suited…
To evaluate the efficacy and safety of intermediate dose LMWH versus fixed low dose LMWH in pregnant women with a history of previous VTE.
PART B (FL phase IIb *PARADIGME*):Primary objective:Randomised section of Part B- To evaluate the efficacy of the *40/15* dose regimen (40 mg lilotomab / 15 MBq/kg Betalutin) compared with *100/20* dose regimen (100 mg/m2 lilotomab/ 20 MBq/kg…